Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline

JAMA

Volumn 283, Issue 12, 2000, Pages 1571-1577

  Näslund, Jan ^a   Haroutunian, Vahram ^b   Mohs, Richard ^b   Davis, Kenneth L ^b   Davies, Peter ^c   Greengard, Paul ^a   Buxbaum, Joseph D ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN PROTEIN; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; PROTEIN CONFORMATION;

EID: 0038117796     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.12.1571     Document Type: Article

References (30)

1. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science. 1997;275:630-631.
2. Haass C, Selkoe DJ. Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide. Cell. 1993;75:1039-1042.
3. Jarrett JT, Lansbury PT Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 1993;73:1055-1058.
4. Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals. Neuron. 1994;13:45-53.
5. Iwatsubo T, Mann DM, Odaka A, et al. Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in Down syndrome. Ann Neurol. 1995;37:294-299.
6. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 1997;20:154-159.
7. Spillantini MG, Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 1998;21:428-433.
8. Davis JN II, Chisholm JC. The "amyloid cascade hypothesis" of AD: decoy or real McCoy? Trends Neurosci. 1997;20:558-559.
9. Haroutunian V, Perl DP, Purohit DP, et al. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol. 1998;55:1185-1191.
10. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572.
11. Heyman A, Wilkinson WE, Hurwitz BJ, et al. Early-onset Alzheimer's disease: clinical predictors of institutionalization and death. Neurology. 1987;37:980-984.
12. Haroutunian V, Purohit DP, Perl DP, et al. Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch Neurol. 1999;56:713-718.
13. Davis KL, Mohs RC, Marin D, et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 1999;281:1401-1406.
14. Bierer LM, Haroutunian V, Gabriel S, et al. Neurochemical correlates of dementia severity in Alzheimer's disease. J Neurochem. 1995;64:749-760.
15. Näslund J, Schierhorn A, Hellman U, et al. Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A. 1994;91:8378-8382.
16. Desdouits F, Buxbaum JD, Desdouits-Magnen J, Nairn AC, Greengard P. Amyloid α peptide formation in cell-free preparations: regulation by protein kinase C. J Biol Chem. 1996;271:24670-24674.
17. Ikonomovic MD, Mizukami K, Davies P, et al. The loss of GluR2(3) immunoreactivity precedes neurofibrillary tangle formation in the entorhinal cortex and hippocampus of Alzheimer brains. J Neuropathol Exp Neurol. 1997;56:1018-1027.
18. Myers JL. Fundaments of Experimental Design. 2nd ed. Boston, Mass: Allyn & Bacon; 1973.
19. Tamaoka A, Fraser PE, Ishii K, et al. Amyloid-β-protein isoforms in brains of subjects with PS1-linked, βAPP-linked and sporadic Alzheimer disease. Brain Res Mol Brain Res. 1998;56:178-185.
20. Mirra SS, Heyman A, McKeel D, et al. for the Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-486.
21. Jicha GA, Bowser R, Kazam IG, Davies P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res. 1997;48:128-132.
22. Arrigada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992;42:631-639.
23. Roses AD. Apolipoprotein E affects the rate of Alzheimer disease expression. J Neuropathol Exp Neurol. 1994;53:429-437.
24. Cummings BJ, Cotman CW. Image analysis of β-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet. 1995;346:1524-1528.
25. Cummings BJ, Pike CJ, Shankle R, Cotman CW. β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging. 1996;17:921-933.
26. Kanne SM, Balota DA, Storandt M, McKeel DW Jr, Morris JC. Relating anatomy to function in Alzheimer's disease. Neurology. 1998;50:979-985.
27. Giannakopoulos P, Hof PR, Giannakopoulos AS, et al. Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of very old patients. Arch Neurol. 1995;52:1150-1159.
28. Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 1996;16:921-932.
29. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease. Am J Psychiatry. 1994;151:1105-1113.
30. McGeer PL, McGeer EG. The inflammatory response system of brain. Brain Res Brain Res Rev. 1995; 21:195-218.